Hannover, Universiẗat, Diss., 2002.

Hannover, Universiẗat, Diss., 2002.

Das Ovarialkarzinom stellt einen häufigen maligen Tumor der Frau dar, der meist spät diagnostiziert wird. Therapeutische Optionen sind nur eingeschränkt verfügbar und nebenwirkungsbehaftet. In der modernen Tumortherapie sind zielgerichtete medikamentöse Ansätze von immer größer Bedeutung und sind bei verschiedenen Entitäten bereits zugelassen. Da Ovarialkarzinome häufig GnRH-Rezeptoren exprimieren, stellt dies einen guten Angriffspunkt für mögliche Therapeutika dar. In dieser Arbeit wurde die Wirkung von Disorazol, einem potenten Zytotoxin, in Kopplung an GnRH auf Ovarialkarzinom-Zellen untersucht. Unter anderem wurden hierbei RT-PCR, Kristallviolettversuche, WST-Versuche und FACS-Analysen durchgeführt. Molekularbiologisch war eine deutliche Expression von GnRH-Rezeptoren auf ovarialen Karzinomzellen zu sehen. Es zeigte sich eine spezifische Toxizität von GnRH-Disorazol-Konjugaten auf Ovarialkarzinom-Zelllinien und andere GnRH-tragende Zellen. Lymphozyten aus dem peripheren Blut waren nicht im besonderen Maße anfällig für Disorazol. Verapamil konnte in einzelnen Zelllinien die Toxizität des Konjugats verstärken, eine Cisplatin-Resistenz hatte jedoch keinen Einfluss darauf. Apoptose-inhibierende Substanzen wie zVAD verminderten den Anteil an toten Zellen, Necrostatin war dazu nicht in der Lage. Die spezifische Wirksamkeit von GnrH gekoppeltem Disorazol auf Ovarialkarzinomzellen bestätigt das ursprüngliche Therapiekonzept. Eine ausgeprägtere Hämatotoxizität konnte nicht nachgewiesen werden, was im Hinblick auf den klinischen Einsatz eine bedeutende Rolle spielt. Da einige weitere Entitäten wie das triple-negative Mamma-Karzinom GnRH-Rezeptor-exprimierende Zellen aufweisen, ist ein Einsatz auch in diesen Krankheitsbildern denkbar. / Ovarian cancer is a frequent gynecological malignant disease with poor prognosis due to late diagnosis. Therapeutic options are limited. In modern oncologic treatment approaches, targeted therapy is a well-known therapeutic principle. Since ovarian cancer cells can express GnRH receptors, this can be used as a medical target. We investigated the toxic effect of conjugates consisting of Disorazol and GnRH on ovarian cancer cell lines. Among others RT-PCR, cristal violett assays, WST-assays and FACS-analysis were performed. RT-PCR revealed expression of the GnRH receptor in ovarian cancer cells. There was specific toxicity of GnRH-Disorazol-conjugates on cell lines representing ovarian cancer. In contrast, peripheral blood lymphocytes were not especially sensitive for Disorazol. Verapamil was able to enhance toxicity in distinct cell lines; Cisplatin resistant cell lines were sensitive for the conjugate too. Substances inhibiting apoptosis like z-VAD could decrease the amount of dead cells, whereas necrostatin had no effect. The specific toxicity of disorazol-GnRH-conjugates on ovarian cancer cells proofed the principle of this targeted therapy approach. Human lymphocytes were not especially sensitive to the toxin, which could play an important role with regard to the clinical use. Since other cancerous tissues like the triple negative breast cancer express GnRH receptors, this therapeutic approach could be reasonable in those entities.

A highly convergent strategy for the synthesis of the antitubulin polyketide disorazole C1 is proposed based around the alkyne precursor I, featuring a novel Evans-Tishchenko/ring closing alkyne metathesis approach. Due to the inherent symmetry of the molecule this retrosynthesis leads to two fragments: a β- hydroxyketone II and the oxazole C(1)-(9) fragment III. A review of previous syntheses of disorazole C1 and established structure activity relationships (SARs) highlights a gap in current knowledge relating to the role of the oxazole in tubulin binding. Therefore, the focus of this research has been towards developing new routes for the synthesis of the C(1)-C(9) fragment that can be adapted to the synthesis of heterocyclic analogues to further establish the SAR of disorazole C1. Chapter 2 focuses on a disconnection at the C(5)-C(6) bond and a novel synthesis of the racemic C(1)-C(9) fragment has been achieved via a lithiation of methyl 2- methyl-1,3-oxazole-4-carboxylate and coupling to aldehyde V. First generation asymmetric routes to the C(1)-C(9) fragment centred on i. a biomimetic amino acid condensation route via an oxazoline intermediate based on the precedent of Meyers et al. and ii. a C(4)-C(5) disconnection approach based around the epoxide VII; are discussed in chapter 3. A second generation C(4)-C(5) disconnection centred on the novel tosylate VIII is discussed in chapter 4. Attempts to synthesise the parent C(1)- C(9) oxazole fragment using the tosylate VIII via i. a palladium catalysed C-H activation of ethyl 4-oxazole carboxylate and ii. lithiation of oxazole are reported. Coupling of fragment VIII (X = OTs) with ethyl 1H-pyrazole-4-carboxylate and a CuAAC coupling of the azide derived from tosylate VIII with methyl propiolate has allowed the successful completion of the synthesis of pyrazole and triazole analogues of this fragment.

Structure-activity relationships (SARs) in the disorazole family have been revealed through the biological testing of natural disorazoles and their synthetic analogues, but little is known about the contribution of the oxazole to the anti-tubulin activity of disorazole C1 I. The development of a novel Evans-Tishchenko/alkyne metathesis (ET-AM) route towards the synthesis of disorazole C1 will provide straightforward access to disorazole C1 and its heterocyclic analogues, thus allowing the contribution of the oxazole to the natural product's bioactivity to be elucidated. Our ET-AM approach offers a highly diastereoselective and convergent means of constructing heterocyclic analogues of the disorazole C1 scaffold Het-II. It is envisaged that ET coupling of C(1)-C(9) aldehydes Het-IV to the C(10)-C(19) β-hydroxyketone V will give the key, requisite, 1,3-anti diol monoester bis-alkynes Het-III for dimerisation via an alkyne cross-metathesis/ring-closing alkyne metathesis (ACM-RCAM) reaction. Further diversification may be achieved through the synthesis of C(6)-heteroatom analogues of the C(1)-C(9) fragment Het-IV. Chapter 2 outlines efforts towards the synthesis of C(6)-amino analogues Het-VI of the C(1)-C(9) fragment IV. Elaboration of Garner's aldehyde VIII allowed the synthesis of the N-protected C(5)-C(9) mesylate VII; an analogue of an advanced C(1)-C(9) fragment intermediate. A scalable route towards the synthesis of the C(10)-C(19) fragment V and investigations into its reactivity under ET coupling conditions are critical to the success of our ET-AM approach. Chapter 3 details convergent approaches towards the synthesis of the C(10)-C(19) β-hydroxyketone V, which centred around: (i) an olefin cross-metathesis reaction [C(11)-C(12) disconnection]; (ii) an epoxide ringopening reaction [C(12)-C(13) disconnection]; and (iii) a Mukaiyama aldol reaction [C(14)-C(15) disconnection]. Chapter 4 describes our successful linear synthesis of the β-hydroxyketone V. Gram-scale preparation of the C(10)-C(19) fragment V permitted investigation into the viability of the ET reaction as a fragment coupling strategy, the results of which are reported in Chapter 5. Although many (hetero)aryl aldehydes failed to react, the successful coupling of electron-deficient substrates allowed a contingency strategy to be explored through preparation of the mono-protected diol IX. Esterification of IX with the carboxylic acid derivative of the C(1)-C(9) oxazole has allowed generation of the C(1)-C(9)/C(10')-C(19') bis-alkyne X required for future AM investigations.

Thesis advisor: Amir H. Hoveyda / Chapter 1: Efficient Z-Selective Cross-Metathesis of Secondary Allylic Ethers Efficient Z-selective cross-metathesis of secondary allylic ethers were catalyzed by monoaryloxide monopyrrolide molybdenum complexes. Reactions involving both silyl and benzyl protected ethers were demonstrated, as well as ethers containing alkyl, aryl and alkynyl substituents. Mechanistic studies were performed, and the reactions were applied to the total synthesis of several ene-diyne natural products. Chapter 2. Stereoselective Total Synthesis of Disorazole C1 The stereoselective total synthesis of disorazole C1 is reported. The synthesis was completed in 12 longest linear steps. Our synthesis demonstrates the utility of Z-selective cross-metathesis to form both alkenyl borons and alkenyl halides. Another key transformation was a one-pot Suzuki-dimerization reaction to form a symmetric 30 membered ring in relatively high yield. Chapter 3. Stereoselective Cross-Metathesis to Form Trisubstituted Alkenes Initial studies into the stereoselective formation of trisubstituted olefins through molybdenum catalyzed cross-metathesis have been performed. Our mechanistic understanding of the reaction lead us to focus on the synthesis of alkenyl halides, which can be obtained in up 90% yield and 75:25 E:Z selectivity. Chapter 4: Ring-Closing Metathesis in the Synthesis of Natural Products Development of highly efficient and selective ring-closing metathesis reactions have enabled collaborators to successfully implement routes in total synthesis endeavors. A diastereoselective seven-membered ring-closing metathesis enabled the successful synthesis of (±)-tetrapetalone A methyl-aglycon. An enantioselective ring-closing metathesis to form a six membered ring has provided access to enantioenriched aspidosperma alkaloids. / Thesis (PhD) — Boston College, 2016. / Submitted to: Boston College. Graduate School of Arts and Sciences. / Discipline: Chemistry.